Venetoclax plus hypomethylating agents in newly diagnosed acute myeloid leukemia patients with RUNX1::RUNX1T1: a retrospective propensity score matching study

Venetoclax plus hypomethylating agents in newly diagnosed acute myeloid leukemia patients with RUNX1::RUNX1T1: a retrospective propensity score matching study

Bibliographic Details
Main Authors:	Miao Wang, Han-Yu Cao, Kai-Wen Tan, Qiao-Cheng Qiu, Yuan-Hong Huang, Shuai-shuai Ge, Zi-Hao Wang, Jia Chen, Xiao-Wen Tang, De-Pei Wu, Sheng-Li Xue, Zheng Li, Hai-Ping Dai
Format:	Article
Language:	English
Published:	Nature Publishing Group 2023-11-01
Series:	Blood Cancer Journal
Online Access:	https://doi.org/10.1038/s41408-023-00948-x

Similar Items

Volunteer unrelated donor cell‐derived acute myeloid leukemia with RUNX1‐RUNX1T1
by: Shinya Hagiwara, et al.
Published: (2021-05-01)

Comprehensive Mutation Profile in Acute Myeloid Leukemia Patients with RUNX1-RUNX1T1 or CBFB-MYH11 Fusions
by: Wei Qin, et al.
Published: (2022-05-01)

Prognostic Impacts of D816V <i>KIT</i> Mutation and Peri-Transplant <i>RUNX1–RUNX1T1</i> MRD Monitoring on Acute Myeloid Leukemia with <i>RUNX1–RUNX1T1</i>
by: Byung-Sik Cho, et al.
Published: (2021-01-01)

Outcomes of Newly Diagnosed Acute Myeloid Leukemia Patients Treated With Hypomethylating Agents With or Without Venetoclax: A Propensity Score-Adjusted Cohort Study
by: Moaath K. Mustafa Ali, et al.
Published: (2022-03-01)

Family platelet disorder with propensity to acute myeloid leukemia: new family with RUNX1 mutation
by: V. O. Bobrynina, et al.
Published: (2014-07-01)

Family platelet disorder with propensity to acute myeloid leukemia: new family with RUNX1 mutation
by: V. O. Bobrynina, et al.
Published: (2014-07-01)

Cdk6 blocks myeloid differentiation by interfering with Runx1 DNA binding and Runx1-C/EBPalpha interaction.
by: Fujimoto, T, et al.
Published: (2007)

Acute myeloid leukemia with concurrent NPM1 and RUNX1 mutations
by: Zhuang Zuo, et al.
Published: (2023-01-01)

Complex rearrangement in acute myeloid leukemia M2 with RUNX1/RUNX1T1 fusion involving chromosomes 8, 17 and 21
by: Shiba Ranjan Mishra, et al.
Published: (2021-05-01)

Hemophagocytic Lymphohistiocytosis in RUNX1: : RUNX1T1 Positive AML with Blast Count Below 20%
by: Xingqin Huang, et al.
Published: (2023-08-01)

RUNX1-Regulated Pathways and Biomarkers in Acute Myeloid Leukaemia
by: Deepesh Kumar Verma, et al.
Published: (2023-03-01)

RUNX1/RUNX1T1 mediates alternative splicing and reorganises the transcriptional landscape in leukemia
by: Vasily V. Grinev, et al.
Published: (2021-01-01)

CD82 hypomethylation is essential for tuberculosis pathogenesis via regulation of RUNX1-Rab5/22
by: Hyun-Jung Koh, et al.
Published: (2018-05-01)

Efficacy of venetoclax combined with hypomethylating agents in young, and unfit patients with newly diagnosed core binding factor acute myeloid leukemia
by: Keyuan Zhang, et al.
Published: (2023-10-01)

Azacitidine Plus Venetoclax for the Treatment of Relapsed and Newly Diagnosed Acute Myeloid Leukemia Patients
by: Sylvain Garciaz, et al.
Published: (2022-04-01)

RUNX1T1 function in cell fate
by: Nan Hu, et al.
Published: (2022-07-01)

The dynamics of RUNX1-RUNX1T1 transcript levels after allogeneic hematopoietic stem cell transplantation predict relapse in patients with t(8;21) acute myeloid leukemia
by: Ya-Zhen Qin, et al.
Published: (2017-02-01)

Myeloid/Lymphoid Neoplasm With FGFR1 Rearrangement Accompanying RUNX1 and NOTCH1 Gene Mutations
by: Xiaoxue Wang, et al.
Published: (2019-11-01)

Safety and Efficacy: Clinical Experience of Venetoclax in Combination With Hypomethylating Agents in Both Newly Diagnosed and Relapsed/Refractory Advanced Myeloid Malignancies
by: Jonathan Feld, et al.
Published: (2021-04-01)

A Runx1-Smad6 rheostat controls Runx1 activity during embryonic hematopoiesis.
by: Knezevic, K, et al.
Published: (2011)

RUNX1 mutations promote leukemogenesis of myeloid malignancies in ASXL1-mutated leukemia
by: Rabindranath Bera, et al.
Published: (2019-10-01)

Transcription Factors Runx1 and Runx3 Suppress Keratin Expression in Undifferentiated Keratinocytes
by: Eisaku Ogawa, et al.
Published: (2022-09-01)

Molecular characterization of AML with RUNX1-RUNX1T1 at diagnosis and relapse reveals net loss of co-mutations
by: Alexander Höllein, et al.
Published: (2019-02-01)

Runx1-Runx1t1: comportamiento en pacientes con leucemia mieloide aguda en nuestro medio
by: Heidys Garrote Santana, et al.

The mouse Runx1 +23 hematopoietic stem cell enhancer confers hematopoietic specificity to both Runx1 promoters.
by: Bee, T, et al.
Published: (2009)

A RUNX1-SMAD6 RHEOSTAT CONTROLS RUNX1 LEVELS AND REGULATES HEMATOPOIESIS IN THE DEVELOPING EMBRYO
by: Pimanda, J, et al.
Published: (2010)

Etoposide-induced DNA damage in a chromosomal breakpoint of RUNX1 gene is independent of RUNX1 expression
by: Nicolás Schnake, et al.
Published: (2019-01-01)

MiR144/451 Expression Is Repressed by RUNX1 During Megakaryopoiesis and Disturbed by RUNX1/ETO.
by: Nicole Kohrs, et al.
Published: (2016-03-01)

A Successful Bridge Therapy Combining Hypomethylating Agents with Venetoclax for Adult Patients with Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia
by: Su-Yeon Bang, et al.
Published: (2023-03-01)

Runx1 and Runx2 inhibit fibrotic conversion of cellular niches for hematopoietic stem cells
by: Yoshiki Omatsu, et al.
Published: (2022-05-01)

Deregulated Gene Expression Profiles and Regulatory Networks in Adult and Pediatric RUNX1/RUNX1T1-Positive AML Patients
by: Peggy Kanellou, et al.
Published: (2023-03-01)

RUNX1-ETO and RUNX1-EVI1 Differentially Reprogram the Chromatin Landscape in t(8;21) and t(3;21) AML
by: Justin Loke, et al.
Published: (2017-05-01)

Runx1 and Runx3 are involved in the generation and function of highly suppressive IL-17-producing T regulatory cells.
by: Lequn Li, et al.
Published: (2012-01-01)

Lineage-specific RUNX3 hypomethylation marks the preneoplastic immune component of gastric cancer
by: Kurklu, B, et al.
Published: (2017)

PB1861: EFFICACY AND TOXICITY OF VENETOCLAX PLUS HYPOMETHYLATING AGENTS IN THE REAL LIFE OF ACUTE MYELOID LEUKEMIA
by: Gianluca Martini, et al.
Published: (2023-08-01)

Runx1t1 promotes the neuronal differentiation in rat hippocampus
by: Linqing Zou, et al.
Published: (2020-04-01)

CSF3R T618I Collaborates With RUNX1-RUNX1T1 to Expand Hematopoietic Progenitors and Sensitizes to GLI Inhibition
by: Anja S. Swoboda, et al.
Published: (2023-10-01)

RUNX1 Mutations in Inherited and Sporadic Leukemia
by: Dana C. Bellissimo, et al.
Published: (2017-12-01)

Case Report: Preemptive Treatment With Low-Dose PD-1 Blockade and Azacitidine for Molecular Relapsed Acute Myeloid Leukemia With RUNX1-RUNX1T1 After Allogeneic Hematopoietic Stem Cell Transplantation
by: Yutong Tang, et al.
Published: (2022-02-01)

A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents
by: Nicholas J. Short, et al.
Published: (2023-07-01)